原标题:调节人IgE与桦树花粉主要过敏原Bet v 1结合的单克隆抗体的免疫学特征
——来自浙大迪迅
①背景:近95%的树花粉过敏患者和近70%的水果和蔬菜过敏患者的主要过敏原是Bet v1和同源蛋白。到目前为止,还没有确定Bet v1的连续IgE表位,也有证据表明Bet v1 IgE表位属于构象(不连续)型。②目的:以85只小鼠单克隆抗Bet v1抗体为研究对象,研究人IgE抗体与Bet v1的相互作用。③方法:采用合成重叠多肽图谱和交叉竞争实验对单克隆抗体表位进行鉴定。采用Western blot方法研究了Bet v1特异性单克隆抗体与树花粉、植物性食物过敏原的交叉反应。采用固化重组Bet v1(纯化)竞争实验和嗜碱性组胺释放实验研究了Bet v1特异性单克隆抗体对IgE-Bet v1相互作用的影响。④结果:能使结合到Bet v1的IgE抗体最多可增加5倍,而其他抗体可抑制结合到Bet v1的IgE抗体最多可达99%,并与Bet v1诱导的患者嗜碱性粒细胞组胺释放相竞争。⑤结论: Bet v1特异性抗体的活性被解释为Bet v1状态/IgE表位的稳定性,这些表位要么更易被某些IgE抗体获得,要么被认为具有更高的亲和力。那些与Bet v1 -IgE相互作用竞争的单克隆抗体,如果被人化处理或作为重组抗体片段生产,可能被认为是局部过敏治疗的潜在工具。
延伸阅读
JACI:
[IF:13.1]
Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1
https://doi.org/10.1016/S0091-6749(97)70056-3
Abstract:
Background
Background: Bet v 1 and homologous proteins represent major allergens for almost 95% of patients allergic to tree pollen and approximately 70% of those allergic to fruits and vegetables. As yet, no continuous (sequential) IgE epitopes have been determined for Bet v 1, and evidence has accumulated that Bet v 1 IgE epitopes belong to the conformational (discontinuous) type. Objective: A panel of 85 mouse monoclonal anti-Bet v 1 antibodies was raised as a tool with which to study the interaction of human IgE antibodies with Bet v 1. Methods: The epitopes of selected monoclonal antibodies (mAbs) were characterized by mapping with synthetic overlapping peptides and by cross-competition experiments. Cross-reactivity of Bet v 1–specific mAbs with tree and plant food allergens was investigated by Western blotting. The influence of Bet v 1–specific mAbs on the IgE–Bet v 1 interaction was studied by competition assays with immobilized purified recombinant Bet v 1 and by basophil histamine release experiments. Results: Antibodies that increased the IgE binding to Bet v 1 up to fivefold could be defined, whereas others inhibited IgE binding to Bet v 1 up to 99% and competed with the Bet v 1–induced histamine release from patients' basophils. Conclusion: The activity of the enhancing antibodies is interpreted as a stabilization of Bet v 1 states/IgE epitopes, which are either more accessible for certain IgE antibodies or are recognized with higher affinity. Those mAbs that competed with the Bet v 1–IgE interaction, if humanized or produced as recombinant antibody fragments, might be considered as potential tools for local allergy therapy. (J Allergy Clin Immunol 1997;99:374-84.)
All Author:
Serge Lebecque, MDa, Christiane Dolecek, MDb, Sylvia Lafferb, Vincenzo Visco, PhDa, Stéphanie Denépouxa, Jean-Jacques Pina, Christiane Gureta, George Boltz-Nitulescu, PhDb, Anne Weyer, PhDc, Rudolf Valenta, MDb
2018-12-21 Article
创建过敏性疾病的科研、科普知识交流平台,为过敏患者提供专业诊断、治疗、预防的共享平台。